Safety And Efficacy Of Using A Convenient Dose Schedule Of Plerixafor Instead Of Standard Dose Schedule Of Plerixafor To Facilitate Outpatient Hematopoietic Stem Cell Collection In Multiple Myeloma (MM) Patients Scheduled To Undergo Autologous Hematopoietic Stem Cell Transplantation (HSCT).

Trial Profile

Safety And Efficacy Of Using A Convenient Dose Schedule Of Plerixafor Instead Of Standard Dose Schedule Of Plerixafor To Facilitate Outpatient Hematopoietic Stem Cell Collection In Multiple Myeloma (MM) Patients Scheduled To Undergo Autologous Hematopoietic Stem Cell Transplantation (HSCT).

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Plerixafor (Primary) ; Granulocyte colony-stimulating factors
  • Indications Multiple myeloma; Stem cell mobilisation
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jan 2017 New trial record
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top